New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
13:35 EDTWCG, AGP, AET, HUM, WLP, CNC, HNT, CI, HS, MOH, UNHCMS drops plan to allow insurers to cover fewer drugs, The Hill says
CMS has dropped a plan to give insurers more leeway to limit the number of drugs they cover for Medicare beneficiaries, according to The Hill. Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP). Reference Link
News For HUM;UNH;HNT;AET;MOH;CNC;AGP;HS;WLP;WCG;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 15, 2015
11:08 EDTHUMOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
07:32 EDTWCGWellCare valuation compelling after selloff, says Leerink
Leerink views the valuation of WellCare shares as compelling following the company's "solid" Q1 results. The firm reiterates an Outperform rating on the stock with a $105 price target.
May 14, 2015
07:33 EDTUNHUnitedHealth would consider Optum spinoff if benefits erode, says UBS
Subscribe for More Information
May 13, 2015
11:22 EDTHUMOptions with increasing implied volatility
Subscribe for More Information
10:18 EDTCI, HUM, AETAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
10:01 EDTHUMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:12 EDTCI, HUMHumana downgraded to Underperform from Neutral at Sterne Agee CRT
Sterne Agee CRT analyst Brian Wright downgraded Humana (HUM) to Underperform saying speculation about a takeover is "wishful thinking" at current share levels. The stock rallied 4% yesterday after Leerink told investors that Aetna (AET) may acquire Humana or Cigna (CI) in the near-term. Wright also sees "material" risk to Humana's earnings guidance risk with paid claims outpacing premium growth. He lowered his price target for shares to $150 from $165. Humana shares closed yesterday up $6.76 to $173.38.
May 12, 2015
15:46 EDTHUMHumana May volatility increases on sharp rally
Subscribe for More Information
15:39 EDTCICigna May volatility elevated
Cigna May call option implied volatility is at 35, June is at 28, and August is at 30; compared to its 90-day average of 31, suggesting large near term price movement.
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTHUM, CI, AETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:28 EDTHUMOptions with increasing implied volatility: YELP HUM LULU CTRX
Subscribe for More Information
10:04 EDTHUM, AETHigh option volume stocks
Subscribe for More Information
09:53 EDTHUM, AETAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
07:35 EDTHNTBofA/Merrill to hold a conference
Subscribe for More Information
May 11, 2015
15:06 EDTAETAetna backs FY15 operating EPS $7.20-$7.40, consensus $7.38
In a regulatory filing earlier, Aetna reported that during upcoming investor meetings in May, the company expects to reaffirm its FY15 operating EPS guidance of $7.20-$7.40. Current FY15 EPS consensus is $7.38.
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:22 EDTWCGWellCare recent selloff presents buying opportunity, says Susquehanna
Subscribe for More Information
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information
06:51 EDTAETAetna management to meet with Leerink
Meeting to be held in Hartford, CT on May 11 hosted by Leerink.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use